VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CRDF
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CRDFCardiff Oncology, Inc.
$0.84$65M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CRDF logo

Cardiff Oncology, Inc.

CRDF
NASDAQ · Oncology Biotech
$0.84
At close - Nov 18, 4:00 PM EST - USD
Market Cap$65M
P/E-1.7x
52W High$3.31
Volume853.25K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Challenges Cardiff Oncology Solvency

Cardiff Oncology remains a high-risk, pre-commercial biotechnology firm characterized by a lack of sustainable revenue and a heavy reliance on equity-based financing to fund its clinical pipeline.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CRDF price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-105% Peers

P/E is 105% below peer median

03

Market leadership

RS 24 · Lag

Laggard (Underperforming 76% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CRDF-68.46%
S&P 500 (^GSPC)+6.88%
1-Year Return
CRDF-58.87%
S&P 500 (^GSPC)+10.62%
3-Year Return
CRDF-27.67%
S&P 500 (^GSPC)+63.85%
5-Year Return
CRDF-86.49%
S&P 500 (^GSPC)+38.69%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$593K-13.2% YoY
Net income FY25
-$46M-0.9% YoY
Free cash flow FY25
-$38M-0.5% YoY
Operating margin FY25
-8256.3%-1133.2 pts YoY
ROIC (FY25)-118.9%
Avg ROIC 5Y-62.9%
ROE (TTM)-111.8%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate11/12 (92%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.12+13.0%
vs -$0.14
$171,000+110.0%
vs $81,429
Q3 2026
Aug 11, 2026
-$0.14-17.0%
vs -$0.12
$104,000+65.7%
vs $62,778
Q2 2026
May 14, 2026
-$0.18-38.5%
vs -$0.13
$41,000-53.7%
vs $88,571
Q1 2026
Feb 24, 2026
-$0.11+38.9%
vs -$0.18
$243,000+134.8%
vs $103,500
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·6d ago
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

GlobeNewsWire·Nov 3, 2026
Cardiff Oncology to Participate in the UBS Global Biopharma Conference

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.

GlobeNewsWire·Oct 27, 2026
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer

SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs.

GlobeNewsWire·Oct 21, 2026
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology.

Filtered for Cardiff Oncology, Inc.More Headlines
04

Compare before deciding

Benchmark CRDF against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Cardiff Oncology, Inc. (CRDF)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CRDF logoCRDFCardiff Oncology, Inc.Current
$0.84$64.66M-1.70-13.18%-6735.24%-111.78%—
TGTX logoTGTXTG Therapeutics, Inc.
$66.12$10.12B97.2187.32%11.81%17.62%—
MGNX logoMGNXMacroGenics, Inc.
$1.97$125.22M-2.440.78%-45.37%-142.22%—
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
KPTI logoKPTIKaryopharm Therapeutics Inc.
$0.03$575.64K-0.000.57%-153.28%——

Compare CRDF vs Peers

Cardiff Oncology, Inc. (CRDF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TGTX

Most directly comparable listed peer for CRDF.

Scale Benchmark

vs IQV

Larger-name benchmark to compare CRDF against a more recognizable public peer.

Peer Set

Compare Top 5

vs TGTX, MGNX, NKTR, IMVT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CRDF SEC Filings & Documents

Cardiff Oncology, Inc. (CRDF) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 11, 2026·SEC

Material company update

Jul 16, 2026·SEC

Material company update

Jun 11, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 11, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when CRDF posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CRDF Frequently Asked Questions

Cardiff Oncology, Inc. (CRDF) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Cardiff Oncology, Inc.'s revenue?

Cardiff Oncology, Inc. (CRDF) reported $0.6M in revenue over the trailing twelve months. Revenue was $0.6M in fiscal year 2025.

How fast is Cardiff Oncology, Inc. growing?

Cardiff Oncology, Inc. (CRDF) grew revenue by 11.6% over the trailing twelve months, compared with the twelve months before.

Is CRDF profitable?

No. Cardiff Oncology, Inc. (CRDF) reported a net loss of $37.6M over the trailing twelve months.

Dividend & Returns
What is CRDF's return on equity?

Cardiff Oncology, Inc. (CRDF) had a return on equity (ROE) of -111.8% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Cardiff Oncology, Inc.'s free cash flow?

Cardiff Oncology, Inc. (CRDF) had negative free cash flow of $39.9M over the trailing twelve months.

What if you invested $1,000 in CRDF back in 2005?

Total return calculator · dividends reinvested · 21+ years of data

See returns →